SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 2 to
Form 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Alexion Pharmaceuticals, Inc.
-----------------------------
(Exact name of registrant as specified in its charter)
Delaware 13-3648318
- ---------------------------------------- -------------------
(State of incorporation or organization) (IRS Employer
Identification No.)
352 Knotter Drive, Cheshire, Connecticut 06410
- ---------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange
to be so registered on which each class is
to be registered
None None
------------------- ----------------------
Securities to be registered pursuant to Section 12(g) of the Act:
Rights to Purchase Junior Participating Cumulative Preferred
Stock, $1.00 par value per share, of the Registrant
- --------------------------------------------------------------------------------
(Title of Class)
ITEM 1. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED
On February 14, 1997 the Board of Directors of the Registrant
declared a dividend of one preferred stock purchase right (a "Right") for each
outstanding share of Common Stock, par value $.0001 per share (the "Common
Stock") of the Registrant. The Rights were issued to the stockholders of record
on March 6, 1997 and will expire in ten years, subject to earlier redemption.
Under certain circumstances, each Right entitles the registered holder to
purchase from the Registrant one one-hundredth of a share of Junior
Participating Cumulative Preferred Stock, par value $1.00 per share ("Preferred
Stock"), of the Registrant or, in certain circumstances, either Common Stock or
common stock of an acquiring company at one-half the market price of such Common
Stock or common stock, as the case may be. The Rights were designed to make it
more likely that all the Registrant's stockholders receive fair and equal
treatment in the event of any proposed takeover of the Registrant and to guard
against the use of partial tender offers or other coercive tactics to gain
control of the Registrant. The description and terms of the Rights are set forth
in a Rights Agreement (the "Rights Agreement") between the Registrant and
Continental Stock Transfer & Trust Company, as Rights Agent (the "Rights
Agent").
Expiration Date
The expiration date under the Registrant's Shareholder Rights Plan
is March 6, 2007. However, the previously filed Form 8-A including the exhibits
thereto refer to earlier expiration dates. On December 12, 2001, the Board of
Directors of Registrant clarified that the expiration date of the Rights is
March 6, 2007.
Except for the clarification of the expiration date, the terms and conditions of
the Rights remain unchanged from the description contained in the Form 8-A filed
on February 21, 1997 as amended by Amendment No. 1 to Form 8-A filed on October
6, 2000.
A copy of Amendment No. 2 to the Rights Agreement is attached hereto
as Exhibit 10.1 and is incorporated herein by reference.
ITEM 2. EXHIBITS
1. Amendment No. 2 to Rights Agreement, dated as of December 12, 2001,
between the Registrant and Continental Stock Transfer and Trust Company.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities
Exchange Act of 1934, the Registrant has duly caused this Registration Statement
to be signed on its behalf by the undersigned thereto duly authorized.
ALEXION PHARMACEUTICALS, INC.
(Registrant)
By: /s/ Leonard Bell
------------------------------------
Leonard Bell
President
DATE: December 12, 2001
EXHIBIT INDEX
Sequential
Exhibit No. Description Page No.
- ----------- ----------- --------
10.1 Amendment No. 2 to Rights
Agreement, dated as of
December 12, 2001, between the
Registrant and Continental
Stock Transfer and Trust
Company.
Exhibit 10.1
AMENDMENT NO. 2 TO
RIGHTS AGREEMENT
This AMENDMENT NO. 2 RIGHTS AGREEMENT (the "Amendment") is made as
of December 12, 2001 between Alexion Pharmaceuticals, Inc., a Delaware
corporation (the "Company"), and Continental Stock Transfer & Trust Company, a
New York corporation (the "Rights Agent").
WHEREAS, on February 14, 1997, the Board of Directors of the Company
declared a dividend of one preferred stock purchase right ("Right") for each
share of Common Stock, par value $.0001 per share, of the Company outstanding at
the close of business on March 6, 1997; and
WHEREAS, each Right entitles the registered holder thereof to
purchase from the Company one one-hundreth (1/100 th) of a share of Junior
Participating Cumulative Preferred Stock, par value $1.00 per share, of the
Company or, in certain circumstances, either Common Stock of the Company or
common stock of an acquiring company at one-half the market price of the Common
Stock of the Company; and
WHEREAS, the description and terms of the Rights are set forth in a
Rights Agreement (the "Rights Agreement") between the Company and the Rights
Agent; and
WHEREAS, the expiration date of the exercise of the Rights is set
forth in the Rights Agreement; and
WHEREAS, the Company desires to amend the Rights Agreement in order
to clarify, the actual date that is the Expiration Date; and
WHEREAS, the Expiration Date referred to in the Rights Agreement has
not occurred;
NOW, THEREFORE, in consideration of the premises and the agreements
set forth herein, the parties hereby agree as follows:
1. Expiration Date. Section 7(a) of the Agreement is hereby amended in its
entirety to read as follows:
"(a) Subject to Section 7(e) hereof, the registered holder of any Right
Certificate may exercise the Rights evidenced thereby (except as otherwise
provided herein) in whole or in part at any time after the Distribution Date
provided herein) in whole or in part at any time after the Distribution Date
upon surrender of the Right Certificate, with the form of election to purchase
and certificate on the reverse side thereof duly executed, to the Rights Agent
at the principal office of Rights Agent in New York, New York, together with
payment of the Purchase Price for each one one-hundredth of a share of Preferred
Stock as to which the Rights are exercised, at or prior to the earliest of (i)
Close of Business on March 6, 2007 (the "Final Expiration Date"), (ii) the time
at which the Rights are redeemed as provided in Section 23, (iii) the time at
which the Rights are exchanged as provided in Section 23A, or (iv) the time at
which the Rights expire pursuant to Section 13(d) (such earliest time being
herein referred to as the "Expiration Date")."
2. Exhibit B. Exhibit B to the Rights Agreement is hereby amended and
restated in its entirety to read as set forth on Exhibit B attached hereto.
3. Exhibit C. Exhibit C to the Rights Agreement is hereby amended and
restated in its entirety to read as set forth on Exhibit C attached hereto.
4. No Further Amendment. Except as expressly amended by this Amendment No.
2, the Rights Agreement shall remain in full force and effect as the same was in
effect immediately prior to the date of this Amendment No. 2.
5. Counterparts. This Amendment may be executed in any number of
counterparts and each of such counterparts shall for all purposes be deemed to
be an original, and all such counterparts shall together constitute but one and
the same instrument.
IN WITNESS WHEREOF, the undersigned have duly executed this Amendment as
of the date first above written.
ATTEST: ALEXION PHARMACEUTICALS, INC.
By: /s/ David Keiser By: /s/ Leonard Bell
----------------------------- ------------------------------------
Name: David Keiser Name: Leonard Bell
Title: Chief Financial Officer Title: President
ATTEST: CONTINENTAL STOCK TRANSFER &
TRUST COMPANY
By: /s/ Thomas Jennings By: /s/ William F. Seegraber
----------------------------- ------------------------------------
Name: Thomas Jennings Name: William F. Seegraber
Title: Asst. Secretary Title: Vice President
EXHIBIT B
[Form of Right Certificate]
Certificate No. R- _________ Rights
NOT EXERCISABLE AFTER MARCH 6, 2007 OR EARLIER IF NOTICE
OF REDEMPTION IS GIVEN. THE RIGHTS ARE SUBJECT TO
REDEMPTION, AT THE OPTION OF THE COMPANY, AT $.01 PER
RIGHT ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT.
[THE RIGHTS REPRESENTED BY THIS CERTIFICATE WERE ISSUED
TO A PERSON WHO WAS AN ACQUIRING PERSON OR AN ASSOCIATE
OR AFFILIATE THEREOF (AS SUCH TERMS ARE DEFINED IN THE
RIGHTS AGREEMENT). THIS RIGHT CERTIFICATE AND THE RIGHTS
REPRESENTED HEREBY MAY BECOME NULL AND VOID AS PROVIDED
IN SECTION 7(e) OF THE RIGHTS AGREEMENT.]*
Right Certificate
ALEXION PHARMACEUTICALS, INC.
This certifies that _________________, or registered assigns, is the
registered owner of the number of Rights set forth above, each of which entitles
the owner thereof, subject to the terms, provisions and conditions of the Rights
Agreement dated as of February 14, 1997 (the "Rights Agreement") between Alexion
Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and Continental
Stock Transfer & Trust Company, a New York corporation (the "Rights Agent"), to
purchase from the Company at any time after the Distribution Date (as such term
is defined in the Rights Agreement) and prior to 5:00 P.M. (New York City time)
on March 6, 2007, at the principal office of the Rights Agent, or its successors
as Rights Agent, in New York, New York, one
- ----------
*The portion of the legend in brackets shall be inserted only if
applicable.
one-hundredth of a share of Junior Participating Cumulative Preferred Stock, par
value $1.00 per share (the "Preferred Stock"), of the Company, at a purchase
price of $725.00 per share the "Purchase Price") in cash, or by certified bank
check or money order payable to the order of the Company, upon presentation and
surrender of this Right Certificate with the Form of Election to Purchase duly
executed. The number of Rights evidenced by this Right Certificate (and the
number of shares which may be purchased upon exercise thereof) set forth above,
and the Purchase Price per share set forth above, are the number and Purchase
Price as of March 6, 1997 based on the shares of Preferred Stock of the Company
as constituted at such date.
As provided in the Rights Agreement, the Purchase Price and the
number of one one-hundredths of a share of Preferred Stock or other securities
which may be purchased upon the exercise of the Rights evidenced by this Right
Certificate are subject to modification and adjustment upon the happening of
certain events.
This Right Certificate is subject to all of the terms, provisions
and conditions of the Rights Agreement, which terms, provisions and conditions
are hereby incorporated herein by reference and made a part hereof and to which
Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities hereunder of the
Rights Agent, the Company and the holders of the Right Certificates. Copies of
the Rights Agreement are on file at the principal executive offices of Alexion
Pharmaceuticals, Inc. and the above-mentioned office of the Rights Agent.
This Right Certificate, with or without other Right Certificates,
upon surrender at the principal office of the Rights Agent, may be exchanged for
another Right Certificate or Rights Certificates of like tenor and date
evidencing Rights entitling the holder to purchase a like aggregate number of
one one-hundredths of a share of Preferred Stock as the Rights evidenced by the
Right
2
Certificate or Right Certificates surrendered shall have entitled such holder to
purchase. If this Right Certificate shall be exercised in part, the holder shall
be entitled to receive upon surrender hereof another Right Certificate or Right
Certificates for the number of whole Rights not exercised.
Subject to the provisions of the Rights Agreement, the Rights
evidenced by this Certificate may be redeemed by the company at its option at a
redemption price of $.01 per Right. Subject to the provisions of the Rights
Agreement, the Rights evidenced by this Rights Certificate may be exchanged by
the Company in whole or in part for Common Stock of the Company under certain
circumstances.
No fractional shares of Common Stock will be issued upon the
exercise of any Right or Rights evidenced hereby, but in lieu thereof a cash
payment will be made, as provided in the Rights Agreement.
No holder of this Right Certificate shall be entitled to vote or
receive dividends or be deemed for any purpose the holder of Common Stock or of
any other securities of the Company which may at the time be issuable on the
exercise hereof, nor shall anything contained in the Rights Agreement or herein
be construed to confer upon the holder hereof, as such, any of the rights of a
stockholder of the Company or any right to vote for the election of directors or
upon any matter submitted to stockholders at any meeting thereof, or to give or
withhold consent to any corporate action, or to receive notice of meetings or
other actions affecting stockholders (except as provided in the Rights
Agreement), or to receive dividends or subscription rights, or otherwise, until
the Right or Rights evidenced by this Right Certificate shall have been
exercised as provided in the Rights Agreement.
This Right Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Rights Agent.
3
[Form of Reverse Side of Right Certificate]
FORM OF ASSIGNMENT
(To be executed by the registered holder if such holder desires to transfer the
Right Certificate.)
FOR VALUE RECEIVED ________________ hereby sells, assigns and
transfers unto ________________________________
(Please print name and address of transferee)
this Right Certificate, together with all right, title and interest therein, and
does hereby irrevocably constitute and appoint ________________ Attorney, to
transfer the within Right Certificate on the books of the within named Company,
with full power of substitution.
Dated: __________, __
________________________________________
Signature
Signatures Guaranteed:
The undersigned hereby certifies that the Rights evidenced by this
Right Certificate are not beneficially owned by an Acquiring Person or an
Affiliate or Associate thereof (as defined in the Rights Agreement).
________________________________________
Signature
4
NOTICE
The signature to the foregoing Assignment must correspond to the
name as written upon the face of this Right Certificate in every particular,
without alteration or enlargement or any change whatsoever.
5
FORM OF ELECTION TO PURCHASE
(To be executed if holder desires to
exercise the Right Certificate.)
To Alexion Pharmaceuticals, Inc.:
The undersigned hereby irrevocably elects to exercise
__________________ Rights represented by this Right Certificate to purchase the
shares of Preferred Stock issuable upon the exercise of such Rights and requests
that certificates for such shares be issued in the name of:
Please insert social security
or other identifying number
__________________________________
(Please print name and address)
__________________________________
If such number of Rights shall not be all the Rights evidenced by this Right
Certificate, a new Right Certificate for the balance remaining of such Rights
shall be registered in the name of and delivered to:
Please insert social security
or other identifying number
__________________________________
(Please print name and address)
__________________________________
Dated: ______________, __
6
[Form of Election to Purchase -- continued]
________________________________________
Signature
(Signature must conform in all respects
to name of holder as specified on the
face of this Right Certificate.)
Signature Guaranteed:
_________________________________
(To be completed if applicable)
The undersigned hereby certifies that the Rights evidenced by this Right
Certificate are not beneficially owned by an Acquiring Person or an Affiliate or
Associate thereof (as defined in the Rights Agreement).
________________________________________
Signature
_________________________________
NOTICE
In the event the certification set forth above in the Forms of
Assignment and Election is not completed, the Company will deem the beneficial
owner of the Rights evidenced by this Right Certificate to be an Acquiring
Person or an Affiliate or Associate thereof (as defined in the Rights Agreement)
and, in the case of an Assignment, will affix a legend to that effect on any
Right Certificates issued in exchange for this Rights Certificate.
7
EXHIBIT C
ALEXION PHARMACEUTICALS, INC.
SUMMARY OF RIGHTS TO PURCHASE
PREFERRED STOCK
On February 14, 1997, the Board of Directors of Alexion
Pharmaceuticals, Inc. (the "Company") declared a dividend distribution of one
preferred stock purchase right (a "Right") for each outstanding share of Common
Stock, par value $.0001 per share (the "Common Stock"), of the Company. The
distribution is payable on March 6, 1997 to the stockholders of record on March
6, 1997. Each Right entitles the registered holder to purchase from the Company
one one-hundredth of a share of Junior Participating Cumulative Preferred Stock,
par value $1.00 per share ("Preferred Stock") at a price of $725.00 per one
one-hundredth of a share (the "Purchase Price"), subject to adjustment. The
description and terms of the Rights are set forth in a Rights Agreement (the
"Rights Agreement") between the Company and Continental Stock Transfer & Trust
Company, as Rights Agent (the "Rights Agent").
Until the earlier to occur of (i) ten business days following the
time (the "Stock Acquisition Date") of a public announcement or notice to the
Company that a person or group of affiliated or associated persons has acquired
beneficial ownership (as defined in the Rights Agreement) of 20% or more of the
outstanding shares of Common Stock of the Company (such 20% beneficial owner, an
"Acquiring Person"), or (ii) ten business days, or such later date as may be
determined by the Board of Directors of the Company, after the date of the
commencement or announcement by a person of an intention to make a tender offer
or exchange offer for an amount of Common Stock which, together with the shares
of such stock already owned by such person, constitutes 20% or more of the
outstanding shares of such Common Stock (the earlier of such dates
being called the "Distribution Date"), the Rights will be evidenced, with
respect to any of the Company's Common Stock certificates outstanding as of
March 6, 1997, by such Common Stock certificate with a copy of this Summary of
Rights attached thereto. The Rights Agreement provides that, until the
Distribution Date, the Rights will be transferred with and only with the
Company's Common Stock. Until the Distribution Date (or earlier redemption or
expiration of the Rights), new Common Stock certificates issued after March 6,
1997, upon transfer or new issuance of the Company's Common Stock, will contain
a notation incorporating the Rights Agreement by reference. Until the
Distribution Date (or earlier redemption or expiration of the Rights), the
surrender for transfer of any of the Company's Common Stock certificates
outstanding as of March 6, 1997, even without a copy of this Summary of Rights
attached thereto, will also constitute the transfer of the Rights associated
with the shares of Common Stock represented by such certificate. As soon as
practicable following the Distribution Date, separate certificates evidencing
the Rights ("Right Certificates") will be mailed to holders of record of the
Company's Common Stock as of the close of business on the Distribution Date and
such separate Right Certificates alone will evidence the Rights.
The Rights are not exercisable until the Distribution Date. The Rights
will expire on March 6, 2007, unless earlier redeemed by the Company as
described below.
The Purchase Price payable, and the number of shares of Preferred Stock or
other securities or property issuable upon exercise of the Rights, are subject
to adjustment from time to time to prevent dilution (i) in the event of a stock
dividend on, or a subdivision, combination or reclassification of the Preferred
Stock, (ii) upon the fixing of a record date for the issuance to holders of
Preferred Stock of certain rights, options or warrants to subscribe for shares
of Preferred Stock
2
or convertible securities at less than the current market price of shares of
Preferred Stock or (iii) upon the fixing of a record date for the making of a
distribution to holders of shares of Preferred Stock of evidences of
indebtedness or assets (excluding regular periodic cash dividends not exceeding
125% of the last regular periodic cash dividend or dividends payable in shares
of Preferred Stock) or of subscription rights or warrants (other than those
referred to above). The number of Rights and number of shares of Preferred Stock
issuable upon the exercise of each Right are also subject to adjustment in the
event of a stock split, combination or stock dividend on the Common Stock prior
to the Distribution Date.
In the event that after the Stock Acquisition Date the Company is
acquired in a merger or other business combination transaction or 50% or more of
its assets, cash flow or earning power are sold or otherwise transferred, proper
provision shall be made so that each holder of a Right shall thereafter have the
right to receive, upon the exercise thereof at the then current exercise price
of the Right, that number of shares of common stock of the acquiring company
which at the time of such transaction would have a market value (as defined in
the Rights Agreement) of two times the exercise price of the Right. In the event
that the Company were the surviving corporation of a merger and its Common Stock
were changed or exchanged, proper provision shall be made so that each holder of
a Right will thereafter have the right to receive upon exercise that number of
shares of common stock of the other party to the transaction having a market
value of two times the exercise price of the Right.
In the event that a person or group becomes an Acquiring Person
(otherwise than pursuant to a tender offer or exchange offer for all outstanding
shares of Common Stock at a price and on terms which are determined to be fair
and in the best interests of the Company and its
3
stockholders by a majority of the members of the Board of Directors of the
Company who are not Acquiring Persons or representatives or nominees of or
affiliated or associated with an Acquiring Person), proper provision shall be
made so that each holder of a Right, other than Rights that were beneficially
owned by the Acquiring Person, which will thereafter be void, will thereafter
have the right to receive upon exercise that number of shares of Common Stock
having a market value (as defined in the Rights Agreement) of two times the
exercise price of the Right. A person or group will not be deemed to be an
Acquiring Person if the Board of Directors of the Company determines that such
person or group became an Acquiring Person inadvertently and such person or
group promptly divests itself of a sufficient number of shares of Common Stock
so that such person or group is no longer an Acquiring Person.
With certain exceptions, no adjustment in the Purchase Price will be
required until cumulative adjustments require an adjustment of at least 1% in
such Purchase Price. No fractional shares of Common Stock will be issued and, in
lieu thereof, an adjustment in cash will be made based on the market value of
shares of Common Stock on the last trading date prior to the date of exercise.
At any time prior to the earlier of (i) ten business days after the
Stock Acquisition Date and (ii) March 6, 2007, the Company, by resolution of its
Board of Directors, may redeem the Rights in whole, but not in part, at a price
of $0.01 per Right (the "Redemption Price"). If such resolution is adopted
following the Stock Acquisition Date, it will be effective only with the
concurrence of a majority of the members (the "Continuing Directors") of the
Board of Directors of the Company who are not Acquiring Persons or
representatives or nominees of or affiliated or associated with an Acquiring
Person and who either were members of such Board of Directors prior
4
to the Stock Acquisition Date or subsequently became a member and whose election
thereto was approved by a majority of the directors who were not Acquiring
Persons or representatives or nominees of or affiliated or associated with an
Acquiring Person. The Company may, at any time prior to the Stock Acquisition
Date, extend the time in which the Rights may be redeemed. Immediately upon the
action of the Board of Directors of the Company electing to redeem the Rights,
the right to exercise the Rights will terminate and the only right of the
holders of Rights will be to receive the Redemption Price.
At any time after a person becomes an Acquiring Person and prior to
the acquisition by such person of 50% or more of the outstanding Common Stock of
the Company, the Board of Directors of the Company, with the concurrence of a
majority of the Continuing Directors, may exchange the Rights (other than Rights
beneficially owned by such person which have become void), in whole or in part,
for Common Stock of the Company at an exchange ratio of one share of Common
Stock per Right (subject to adjustment).
Each share of Preferred Stock purchasable upon exercise of the
Rights will have a minimum preferential dividend of $10.00 per year, but will be
entitled to receive, in the aggregate, a dividend of 100 times the dividend
declared on a share of Common Stock. In the event of liquidation, the holders of
the shares of Preferred Stock will be entitled to receive a minimum liquidation
payment of $100.00 per share, but will be entitled to receive an aggregate
liquidation payment equal to 100 times the payment to be made per share of
Common Stock. Each share of Preferred Stock will have 100 votes, voting together
with the shares of Common Stock. In addition, if dividends on the Preferred
Stock are in arrears for four consecutive quarterly payment periods, the holders
of the Preferred Stock will have the right, voting as a class, to elect two
members of the
5
Board of Directors. In the event of any merger, consolidation or other
transaction in which shares of Common Stock are exchanged, each share of
Preferred Stock will be entitle to receive 100 times the amount and type of
consideration received per share of Common Stock. The rights of the shares of
Preferred Stock as to dividends and liquidation and in the event of mergers and
consolidations, are protected by antidilution provisions.
Until a Right is exercised, the holder thereof as such, will have no
rights as a stockholder of the Company, including, without limitation, the right
to vote or to receive dividends.
The Rights and the Rights Agreement can be amended by the Board of
Directors of the Company in any respect (including, without limitation, any
extension of the period in which the Rights may be redeemed) at any time prior
to the Stock Acquisition Date. From and after such a time, without the approval
of the stockholders of the Company or the holders of the Rights, the Board of
Directors may only supplement or amend the Rights Agreement in order (i) to cure
any ambiguity, (ii) to correct or supplement any provision contained in the
Rights Agreement which may be defective or inconsistent with any other provision
in the Rights Agreement, (iii) to shorten or lengthen any time period under the
Rights Agreement, or (iv) to make any changes or supplements which the Company
and the Rights Agent may deem necessary or desirable which shall not adversely
affect the interests of the holders of Right Certificates (other than an
Acquiring Person or an affiliate or associate thereof). The Company may, at any
time prior to the Stock Acquisition Date, amend the Rights Agreement to lower
the threshold of Common Stock beneficial ownership at which a person will become
an Acquiring Person to not less than the greater of (i) a percentage larger than
the largest percentage of Common Stock then known by the Company to be
beneficially owned by a person and (ii) 10%.
6
A copy of the Rights Agreement has been filed with the Securities
and Exchange Commission as an Exhibit to a Registration Statement on Form 8-A
dated February 14, 1997. A copy of the Rights Agreement is available free charge
from the Company. This summary description of the Rights does not purport to be
complete and is qualified in its entirety by reference to the Rights Agreement,
which is hereby incorporated herein by reference.
7